CO2020006206A2 - Polimorfos y formas sólidas de un compuesto de pirimidinilamino-pirazol y métodos de producción - Google Patents

Polimorfos y formas sólidas de un compuesto de pirimidinilamino-pirazol y métodos de producción

Info

Publication number
CO2020006206A2
CO2020006206A2 CONC2020/0006206A CO2020006206A CO2020006206A2 CO 2020006206 A2 CO2020006206 A2 CO 2020006206A2 CO 2020006206 A CO2020006206 A CO 2020006206A CO 2020006206 A2 CO2020006206 A2 CO 2020006206A2
Authority
CO
Colombia
Prior art keywords
pyrimidinylamino
polymorphs
production
methods
solid forms
Prior art date
Application number
CONC2020/0006206A
Other languages
English (en)
Inventor
Anantha Sudhakar
Travis Remarchuk
Original Assignee
Denali Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Denali Therapeutics Inc filed Critical Denali Therapeutics Inc
Publication of CO2020006206A2 publication Critical patent/CO2020006206A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La presente descripción hace referencia a formas amorfas y polimórficas cristalinas de 2-metil-2-(3-metil-4-(4-(metilamino)-5-(trifluorometil)pirimidin-2-ilamino)-1H-pirazol-1-il)propanonitrilo o solvatos, tautómeros y cocristales o sales farmacéuticamente aceptables de este, así como a procesos para su elaboración.
CONC2020/0006206A 2017-11-21 2020-05-21 Polimorfos y formas sólidas de un compuesto de pirimidinilamino-pirazol y métodos de producción CO2020006206A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762589276P 2017-11-21 2017-11-21
PCT/US2018/062102 WO2019104086A1 (en) 2017-11-21 2018-11-20 Polymorphs and solid forms of a pyrimidinylamino-pyrazole compound, and methods of production

Publications (1)

Publication Number Publication Date
CO2020006206A2 true CO2020006206A2 (es) 2020-08-10

Family

ID=66631734

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2020/0006206A CO2020006206A2 (es) 2017-11-21 2020-05-21 Polimorfos y formas sólidas de un compuesto de pirimidinilamino-pirazol y métodos de producción

Country Status (22)

Country Link
US (3) US10370361B2 (es)
EP (1) EP3717473B1 (es)
JP (1) JP7303821B2 (es)
KR (1) KR20200089713A (es)
CN (1) CN111819174A (es)
AR (1) AR113893A1 (es)
AU (1) AU2018372180B2 (es)
BR (1) BR112020010215A2 (es)
CA (1) CA3083022A1 (es)
CL (1) CL2020001346A1 (es)
CO (1) CO2020006206A2 (es)
CR (1) CR20200216A (es)
EA (1) EA202091279A1 (es)
IL (1) IL274824A (es)
JO (1) JOP20200128A1 (es)
MA (1) MA51222A (es)
MX (1) MX2020005332A (es)
PE (1) PE20210157A1 (es)
SG (1) SG11202004733WA (es)
TW (1) TWI823878B (es)
UA (1) UA126414C2 (es)
WO (1) WO2019104086A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA51222A (fr) 2017-11-21 2020-10-07 Denali Therapeutics Inc Polymorphes et formes solides d'un composé de pyrimidinylamino-pyrazole, et procédés de production
CA3086182A1 (en) 2017-12-20 2019-06-27 Denali Therapeutics Inc. Process for the preparation of pyrimidinyl-4-aminopyrazole compounds
WO2023174946A1 (en) 2022-03-15 2023-09-21 INSERM (Institut National de la Santé et de la Recherche Médicale) Early and non-invasive method for assessing a subject's risk of having parkinson's disease

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20130216A1 (es) 2010-05-21 2013-02-27 Incyte Corp Formulacion topica para un inhibidor de jak
CN105837519A (zh) 2010-06-04 2016-08-10 霍夫曼-拉罗奇有限公司 作为lrrk2调节剂的氨基嘧啶衍生物
GB201015949D0 (en) 2010-09-22 2010-11-03 Medical Res Council Technology Compounds
RS56583B1 (sr) * 2010-11-10 2018-02-28 Genentech Inc Derivati pirazol aminopirimidina kao lrrk2 modulatori
BR112014009717B1 (pt) 2011-11-29 2022-06-14 Genentech, Inc Derivados de 2-(fenil ou pirid-3-il)aminopirimidina, seus usos, e composição farmacêutica
AR089182A1 (es) 2011-11-29 2014-08-06 Hoffmann La Roche Derivados de aminopirimidina como moduladores de lrrk2
US9145402B2 (en) 2011-11-29 2015-09-29 Genentech, Inc. Aminopyrimidine derivatives as LRRK2 modulators
CA2850594C (en) 2011-11-29 2020-03-10 F. Hoffmann-La Roche Ag Aminopyrimidine derivatives as lrrk2 modulators
CN106220615A (zh) 2012-05-03 2016-12-14 霍夫曼-拉罗奇有限公司 作为lrrk2调节剂的吡唑氨基嘧啶衍生物
CA2871375C (en) 2012-05-03 2020-10-27 F. Hoffmann-La Roche Ag Pyrazole aminopyrimidine derivatives as lrrk2 modulators for use in the treatment of parkinson's disease
HUE056678T2 (hu) * 2016-06-16 2022-02-28 Denali Therapeutics Inc Pirimidin-2-ilamino-1H-pirazolok mint LRRK2 inhibitorok neurodegeneratív rendellenességek kezelésére való alkalmazásra
MA51222A (fr) * 2017-11-21 2020-10-07 Denali Therapeutics Inc Polymorphes et formes solides d'un composé de pyrimidinylamino-pyrazole, et procédés de production

Also Published As

Publication number Publication date
SG11202004733WA (en) 2020-06-29
CR20200216A (es) 2021-03-19
AU2018372180A1 (en) 2020-06-18
JP2021504450A (ja) 2021-02-15
AR113893A1 (es) 2020-06-24
KR20200089713A (ko) 2020-07-27
PE20210157A1 (es) 2021-01-26
US20190194170A1 (en) 2019-06-27
MA51222A (fr) 2020-10-07
UA126414C2 (uk) 2022-09-28
EP3717473A4 (en) 2021-07-07
EA202091279A1 (ru) 2020-08-19
US20190315723A1 (en) 2019-10-17
AU2018372180B2 (en) 2023-08-17
EP3717473B1 (en) 2024-01-10
JP7303821B2 (ja) 2023-07-05
BR112020010215A2 (pt) 2020-11-03
WO2019104086A1 (en) 2019-05-31
EP3717473A1 (en) 2020-10-07
US11427571B2 (en) 2022-08-30
CL2020001346A1 (es) 2020-11-20
TWI823878B (zh) 2023-12-01
IL274824A (en) 2020-07-30
US20210087176A1 (en) 2021-03-25
US10851088B2 (en) 2020-12-01
TW201925190A (zh) 2019-07-01
US10370361B2 (en) 2019-08-06
CA3083022A1 (en) 2019-05-31
JOP20200128A1 (ar) 2020-05-21
CN111819174A (zh) 2020-10-23
MX2020005332A (es) 2021-01-08

Similar Documents

Publication Publication Date Title
CU20170087A7 (es) Formas cristalinas de 5-(4-ciclopropil-1 h-imidazol-1-il)-n-(6-(4-isopropil-4h-1 , 2, 4- triazol-3-il)piridin-2-il)-2-fluoro-4-metilbenzamida
CO2020006206A2 (es) Polimorfos y formas sólidas de un compuesto de pirimidinilamino-pirazol y métodos de producción
DOP2016000281A (es) Compuestos de imidazo[4,5-c]quinolin-2-ona y su uso para tratar cáncer
EA202091115A1 (ru) Производные хиназолина, применяемые для лечения вич
CO2017001884A2 (es) Polimorfos de selinexor
ECSP16067303A (es) Heteroarilos y usos de estos
CU20160188A7 (es) Compuestos de indazole substituidos como inhibidores de irak4
WO2016011390A8 (en) Irak4 inhibiting agents
CR20150472A (es) USO DE DERIVADOS DE PIRAZOLOPIRIMIDINA PARA EL TRATAMIENTO DE TRANSTORNOS RELACIONADOS CON LA PI3Kd
EA201791304A1 (ru) Производные изохинолина для лечения вич
EA201790395A1 (ru) Производные аминотриазина, подходящие для применения в качестве соединений-ингибиторов tank-связывающей киназы
AR102981A1 (es) Inhibidores de la necrosis celular y métodos de preparación de los mismos
AR100818A1 (es) N-(cianometil)-4-(2-(4-morfolinofenilamino)pirimidin-4-il)benzamida
DOP2016000308A (es) Compuestos de 1, 3, 4-tiadiazol y uso de los mismos para el tratamiento del cáncer
CO2019001181A2 (es) Compuestos de heteroarilcarboxamida como inhibidores de ripk2
UY38233A (es) Agentes inhibidores para la tirosina cinasa de bruton
CL2021000276A1 (es) Polimorfo cristalino del clorhidrato de 8-bromo-2-(1-metilpiperidin-4-ilamin)-4-(4-fenoxifenilamin)pirido[4,3-d]pirimidin-5(6h)-ona y método para prepararlo.
AR099766A1 (es) Inhibidores de la quinasa asociada al adaptador 1, composiciones que los comprenden y métodos para utilizarlos
CR20190344A (es) Activador de nrf2
MX2020004050A (es) Intermediario cristalino de linagliptina y proceso para la preparacion de linagliptina.
DOP2015000299A (es) Derivados de prodroga de triazolpiridinas sustituidas
CO2020012574A2 (es) Método para la preparación de una 1,2,4-triazolona 2,4,5-trisustituida
BR112018012095A2 (pt) formas sólidas de compostos substituidos de 5,6-di-hidro-6-fenilbenzo[f]isoquinolin-2-amina
CU20190035A7 (es) Derivados sustituidos de 6-(1h-pirazol-1-il)pirimidin-4-amina
CL2017002180A1 (es) Formas cristalinas de un compuesto de pirrolopiridina